EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug
Portfolio Pulse from Shanthi Rexaline
Swedish biopharma Calliditas Therapeutics AB (NASDAQ:CALT) is making progress in addressing rare kidney diseases with its lead drug, Tarpeyo. The drug has received accelerated FDA approval for treating IgA nephropathy, an autoimmune kidney disorder. Tarpeyo focuses on the origin of the disease and is delivered to the gut. The CEO of Calliditas, Renee Aguiar-Lucander, highlighted two key differentiators for Tarpeyo versus other approaches in chronic kidney disease treatment. The drug can stabilize kidney function and gives the freedom of not necessarily staying on it for the rest of a patient's life. The company is also close to profitability and has a healthy cash balance.
September 08, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas Therapeutics is making progress with its lead drug, Tarpeyo, which has received accelerated FDA approval for treating a rare kidney disorder. The company is also close to profitability.
The progress of Tarpeyo, the lead drug of Calliditas Therapeutics, in treating a rare kidney disorder is a positive development for the company. The fact that the company is close to profitability also bodes well for its financial health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Calliditas Therapeutics' CEO compared Tarpeyo with a rival offering from Travere Therapeutics, Inc. (NASDAQ:TVTX), explaining away the price premium of Tarpeyo.
The comparison of Tarpeyo with a rival offering from Travere Therapeutics by the CEO of Calliditas Therapeutics could have implications for Travere Therapeutics. However, the impact is not clear at this point.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
The stock of Calliditas Therapeutics has fallen 5.2% so far this year, which is in line with the SPDR S&P Biotech ETF (NYSE:XBI), which has clocked a year-to-date loss of 5.1%.
The performance of Calliditas Therapeutics' stock is in line with the broader biotech sector as represented by the SPDR S&P Biotech ETF. This suggests that the company's stock is moving in tandem with the sector.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50